Neurocrine Biosciences (NBIX) Cash from Operations (2010 - 2026)

Neurocrine Biosciences has reported Cash from Operations for 17 years, with the latest figure at 145800000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 125.0% year-over-year to 145800000.0; the trailing twelve-month figure through Mar 2026 stood at 863700000.0 (up 62.99% YoY), and the FY2025 full-year result was 782700000.0, up 31.46% from the prior year.
• Cash from Operations for Q1 2026 stood at 145800000.0, down from 388400000.0 in the prior quarter.
• The five-year high for Cash from Operations was 388400000.0 in Q4 2025, with the low at 125200000.0 in Q1 2023.
• Historically, Cash from Operations has averaged 132541176.47 across 5 years, with a median of 138100000.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Operations soared 3304.76% — and 2023, when it plunged 209.14%.
• Neurocrine Biosciences' Cash from Operations stood at 143000000.0 in 2022, then decreased by 13.64% to 123500000.0 in 2023, then surged by 96.36% to 242500000.0 in 2024, then jumped by 60.16% to 388400000.0 in 2025, then sank by 62.46% to 145800000.0 in 2026.
• The last three Cash from Operations figures came in at 145800000.0 (Q1 2026), 388400000.0 (Q4 2025), and 227500000.0 (Q3 2025), per Business Quant data.